XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Up 31.7% in December

XOMA Royalty Corporation (NASDAQ:XOMA) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 482,452 shares, a growth of 31.7% from the November 30th total of 366,222 shares. Based on an average trading volume of 93,126 shares, the short-interest ratio is currently 5.2 days. Approximately 4.2% of the shares of the stock are short sold. Approximately 4.2% of the shares of the stock are short sold. Based on an average trading volume of 93,126 shares, the short-interest ratio is currently 5.2 days.

XOMA Royalty Stock Performance

NASDAQ:XOMA opened at $25.25 on Tuesday. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 1.07. The firm’s fifty day simple moving average is $30.87 and its 200 day simple moving average is $31.10. The stock has a market cap of $312.60 million, a P/E ratio of 34.12 and a beta of 0.94. XOMA Royalty has a twelve month low of $18.35 and a twelve month high of $39.92.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.33). The company had revenue of $9.35 million during the quarter, compared to the consensus estimate of $11.47 million. XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%. As a group, research analysts predict that XOMA Royalty will post -1.41 EPS for the current year.

Insider Activity at XOMA Royalty

In other XOMA Royalty news, CEO Owen Hughes acquired 100,000 shares of the stock in a transaction dated Thursday, December 4th. The stock was purchased at an average cost of $25.05 per share, for a total transaction of $2,505,000.00. Following the acquisition, the chief executive officer owned 102,000 shares in the company, valued at $2,555,100. The trade was a 5,000.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA Royalty

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of XOMA Royalty by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock worth $25,749,000 after acquiring an additional 29,298 shares during the period. Opaleye Management Inc. lifted its stake in shares of XOMA Royalty by 0.8% in the 2nd quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company’s stock valued at $6,428,000 after purchasing an additional 2,044 shares during the period. Woodline Partners LP boosted its position in shares of XOMA Royalty by 16.5% during the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after purchasing an additional 29,715 shares in the last quarter. Geode Capital Management LLC grew its stake in XOMA Royalty by 9.1% in the second quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock worth $5,132,000 after purchasing an additional 16,929 shares during the period. Finally, Stonepine Capital Management LLC grew its stake in XOMA Royalty by 17.2% in the second quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company’s stock worth $3,834,000 after purchasing an additional 22,330 shares during the period. 95.92% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on XOMA. Stifel Nicolaus set a $50.00 price objective on XOMA Royalty in a research note on Friday, December 12th. HC Wainwright lowered their price target on shares of XOMA Royalty from $104.00 to $97.00 and set a “buy” rating for the company in a report on Thursday, December 11th. UBS Group set a $76.00 price target on shares of XOMA Royalty in a research report on Tuesday, December 9th. Wall Street Zen cut shares of XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Benchmark reaffirmed a “buy” rating on shares of XOMA Royalty in a research note on Friday, December 12th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, XOMA Royalty has an average rating of “Hold” and a consensus price target of $60.60.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.